Literature DB >> 24972699

Effect of rs6923761 gene variant of glucagon-like peptide 1 receptor on metabolic response and weight loss after a 3-month intervention with a hypocaloric diet.

Daniel Antonio de Luis1, Rocío Aller, Olatz Izaola, J J Lopez, E Gomez, B Torres, G Diaz Soto.   

Abstract

BACKGROUND: Studies of the GLP-1 receptor (GLP-1 R) have been directed at identifying polymorphisms in the GLP-1 R gene that may be a contributing factor in the pathogenesis of obesity and cardiovascular risk factors. Nevertheless, the role of GLP-1 R variants on body weight response after dietary intervention has not been evaluated.
OBJECTIVE: We decided to analyze the effects of the rs6923761 GLP-1 R polymorphism on body weight changes and metabolic parameters after 3 months of a hypocaloric diet.
DESIGN: A sample of 91 obese subjects was analyzed in a prospective way. The hypocaloric diet had 1,520 calories per day; 52 % of carbohydrates, 25 % of lipids and 23 % of proteins. Distribution of fats was: 50.7 % of monounsaturated fats, 38.5 % of saturated fats and 11.8 % of polyunsaturated fats.
RESULTS: In both genotype groups (GG vs. GA + AA), weight, body mass index, fat mass, waist circumference, systolic blood pressure, total cholesterol, LDL cholesterol, leptin, insulin and HOMA levels decreased. No statistical differences were detected in these changes between genotypes. In wild group (GG genotype) (pretreatment and posttreatment), BMI, weight, fat mass, waist circumference and triglyceride levels were higher than (GA + AA) group.
CONCLUSION: Our data showed better anthropometric parameters and triglyceride levels in obese subjects with the mutant allele (A) of rs6923761 GLP-1R polymorphism. A lack of association of this polymorphism with weight loss or biochemical changes after a hypocaloric diet was observed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24972699     DOI: 10.1007/s40618-014-0117-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

Review 1.  The glucagon-like peptides.

Authors:  T J Kieffer; J F Habener
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

2.  Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations.

Authors:  Pauli Suominen
Journal:  Clin Chem       Date:  2004-01       Impact factor: 8.327

3.  Validation of a kinetic model for the reactions in RIA.

Authors:  Maria J Duart Duart; Consuelo Olivas Arroyo; José Luis Moreno Frígols
Journal:  Clin Chem Lab Med       Date:  2002-11       Impact factor: 3.694

Review 4.  Adipocytokines: emerging therapeutic targets.

Authors:  Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

5.  The hormone resistin links obesity to diabetes.

Authors:  C M Steppan; S T Bailey; S Bhat; E J Brown; R R Banerjee; C M Wright; H R Patel; R S Ahima; M A Lazar
Journal:  Nature       Date:  2001-01-18       Impact factor: 49.962

6.  A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.

Authors:  Martin Beinborn; Christine I Worrall; Edward W McBride; Alan S Kopin
Journal:  Regul Pept       Date:  2005-08-15

7.  Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.

Authors:  I Shimomura; R E Hammer; S Ikemoto; M S Brown; J L Goldstein
Journal:  Nature       Date:  1999-09-02       Impact factor: 49.962

8.  Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study.

Authors:  Airani Sathananthan; Chiara Dalla Man; Francesco Micheletto; Alan R Zinsmeister; Michael Camilleri; Paula D Giesler; Jeanette M Laugen; Gianna Toffolo; Robert A Rizza; Claudio Cobelli; Adrian Vella
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

9.  Pharmacological characterization of human incretin receptor missense variants.

Authors:  Jean-Philippe Fortin; Jonathan C Schroeder; Yuantee Zhu; Martin Beinborn; Alan S Kopin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

10.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors:  B Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

View more
  5 in total

Review 1.  Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction.

Authors:  Metin Basaranoglu; Gokcen Basaranoglu; Elisabetta Bugianesi
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

2.  Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.

Authors:  V Chedid; P Vijayvargiya; P Carlson; K Van Malderen; A Acosta; A Zinsmeister; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-28       Impact factor: 3.598

Review 3.  Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.

Authors:  Joanna Michałowska; Ewa Miller-Kasprzak; Paweł Bogdański
Journal:  Nutrients       Date:  2021-01-25       Impact factor: 5.717

Review 4.  Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.

Authors:  Jasna Klen; Vita Dolžan
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

5.  Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study.

Authors:  Evangelia Eirini Tsermpini; Katja Goričar; Blanka Kores Plesničar; Anja Plemenitaš Ilješ; Vita Dolžan
Journal:  Front Mol Neurosci       Date:  2022-06-09       Impact factor: 6.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.